Disclosed herein are methods for treatment for proliferative vitreoretinopathy (PVR) by inhibiting the activity of activated transforming growth factor β activated kinase 1 (TAK-1), or activation thereof. Pharmaceutical compositions for use in the described treatments are also provided.